Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

Open access
Madhavan, Mahesh V., Bikdeli, Behnood, Gupta, Aakriti, Jimenez, David, Burton, John R., Der Nigoghossian, Caroline, Chuich, Taylor, Nouri, Shayan Nabavi, Dreyfus, Isaac, Driggin, Elissa, Sethi, Sanjum, Sehgal, Kartik, Chatterjee, Saurav, Ageno, Walter, Madjid, Mohammad, Guo, Yutao, Tang, Liang V., Hu, Yu, Bertoletti, Laurent, Giri, Jay, Cushman, Mary, Quéré, Isabelle, Dimakakos, Evangelos P., Gibson, C. Michael, Lippi, Giuseppe, Favaloro, Emmanuel J., Fareed, Jawed, Tafur, Alfonso J., Francese, Dominic P., Batra, Jaya, Falanga, Anna, Clerkin, Kevin J., Uriel, Nir, Kirtane, Ajay, McLintock, Claire, Hunt, Beverley J., Spyropoulos, Alex C., Barnes, Geoffrey D., Eikelboom, John W., Weinberg, Ido, Schulman, Sam, Carrier, Marc, Piazza, Gregory, Beckman, Joshua A., Leon, Martin B., Stone, Gregg W., Rosenkranz, Stephan, Goldhaber, Samuel Z., Parikh, Sahil A., Monreal, Manuel, Krumholz, Harlan M., Konstantinides, Stavros V., Weitz, Jeffrey I., Lip, Gregory Y. H., The Global COVID-19 Thrombosis Collaborative Group·2020·Thrombosis and Haemostasis

Abstract

Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/s-0040-1713152

Cites

170 of 170 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 170 references

Cited by

See all 258

Metadata

Authors
Madhavan, M. V., Bikdeli, B., Gupta, A., Jimenez, D., Burton, J. R., Der Nigoghossian, C., Chuich, T., Nouri, S. N., Dreyfus, I., Driggin, E., Sethi, S., Sehgal, K., Chatterjee, S., Ageno, W., Madjid, M., Guo, Y., Tang, L. V., Hu, Y., Bertoletti, L., Giri, J., Cushman, M., Quéré, I., Dimakakos, E. P., Gibson, C. M., Lippi, G., Favaloro, E. J., Fareed, J., Tafur, A. J., Francese, D. P., Batra, J., Falanga, A., Clerkin, K. J., Uriel, N., Kirtane, A., McLintock, C., Hunt, B. J., Spyropoulos, A. C., Barnes, G. D., Eikelboom, J. W., Weinberg, I., Schulman, S., Carrier, M., Piazza, G., Beckman, J. A., Leon, M. B., Stone, G. W., Rosenkranz, S., Goldhaber, S. Z., Parikh, S. A., Monreal, M., Krumholz, H. M., Konstantinides, S. V., Weitz, J. I., Lip, G. Y. H., & The Global COVID-19 Thrombosis Collaborative Group
Venue
Thrombosis and Haemostasis
Published
2020-05-30
Volume
120
Issue
07
Pages
1004-1024
ISSN
  • 0340-6245 (ISSN-L)
  • 2567-689X
OpenAlex
W3030604488
Cited by
258
References
170
FWCI
6.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. https://app.cochat.ai/papers/10.1055/s-0040-1713152
The paper
Madhavan, M. V., Bikdeli, B., Gupta, A., Jimenez, D., Burton, J. R., Der Nigoghossian, C., Chuich, T., Nouri, S. N., Dreyfus, I., Driggin, E., Sethi, S., Sehgal, K., Chatterjee, S., Ageno, W., Madjid, M., Guo, Y., Tang, L. V., Hu, Y., Bertoletti, L., . . . The Global COVID-19 Thrombosis Collaborative Group. (2020). Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis. https://doi.org/10.1055/s-0040-1713152

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.